SUPPLEMENTAL LICENSE TERMS Clause Samples
SUPPLEMENTAL LICENSE TERMS. These supplemental license terms ("Supplemental Terms") add to or modify the terms of the Binary Code License Agreement (collectively, the "Agreement"). Capitalized terms not defined in these Supplemental Terms shall have the same meanings ascribed to them in the Agreement. These Supplemental Terms shall supersede any inconsistent or conflicting terms in the Agreement, or in any license contained within the Software.
SUPPLEMENTAL LICENSE TERMS. The Supplemental License Terms below shall take precedence over and supplement the provisions of the present License Agreement with respect to the software products described in more detail below and the affected areas of regulation. Otherwise, the terms of the License Agreement shall apply in unchanged form.
SUPPLEMENTAL LICENSE TERMS. The Open Source Supplemental License Terms sets forth provisions applicable to the Forward Networks Software licensed by End User.
SUPPLEMENTAL LICENSE TERMS. In addition to the license grant and restrictions set forth in Sections 2.1 and 2.2 above, the additional and/or modified terms set forth below shall apply with respect to the specific license type indicated (“Supplemental Terms”). The Supplemental Terms shall control in the event of an inconsistency with Sections 2.1 and/or 2.2 for the applicable license type.
(a) Under a Subscription License: Customer may not decrease its quantity of licenses during the relevant Subscription License Term.
(b) Under a Development License (perpetual and subscription) and/or Build Automation License: Customer may use the Software, during the applicable License Term and subject to the terms and conditions of this Agreement, to create a binary Runtime system image for a Target Platform. If under a perpetual license model, Customer may only use the Software on the Authorized Architecture and only in connection with the Authorized Project as specified in the applicable Order. Customer may not (i) allow access to the Software to anyone other than the Authorized User as specified in the Order; (ii) allow any individual to directly deploy to, or debug on the Target Platform from a Build Automation Server; or (iii) make copies of an SRP and/or KDI for any use other than development and testing without the purchase of a valid Production License.
(c) Under a Production License: Customer may use the Software in a runtime application which is deployed within Customer’s organization, or is sold and/or distributed by Customer, provided that Customer ensures that the terms of this Agreement are referenced and flowed down in any applicable end user license agreements that govern such sale or distribution to third party end users. Customer may only make the quantity of runtime application copies of the Software as specified in the Order.
(d) Under an IR&D License: Customer may use the Software for non-commercial internal research and development, prototyping and proof of concept purposes only.
(e) Under a Source Code license: Customer may: (i) copy the Source Code to a secure storage location that is only accessible to Licensee’s Authorized Users who have a legitimate need to use the Source Code for the Purpose in accordance with the terms of this Agreement on projects and/or programs permitted by a corresponding valid Lynx Development Software License Agreement; (ii) modify the Source Code and create Customer Derivatives solely for the Purpose; (iii) provide Source Code, Software and Docum...
SUPPLEMENTAL LICENSE TERMS. Notwithstanding any other restriction in the Agreement, Insignia may configure the Java Classes pursuant to the Documentation in connection with Insignia Products only. Insignia must use the Java Filter Tool in connection with any such configuration of the Java Classes, and for no other purpose. Insignia agrees and acknowledges that nothing in this Section VII shall otherwise change, eliminate or minimize the restrictions on modification of the Technology under the Agreement. No redistribution license is granted herein for the Java Filter Tool. [*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION, CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
